A novel anti-galectin-9 immunotherapy limits the early progression of pancreatic neoplastic lesions in transgenic mice

BackgroundPancreatic adenocarcinoma (PDAC) is a devastating disease with an urgent need for therapeutic innovation. Immune checkpoint inhibition has shown promise in a variety of solid tumors, but most clinical trials have failed to demonstrate clinical efficacy in PDAC. This low efficacy is partly...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Alexandre Quilbe, Rami Mustapha, Belinda Duchêne, Abhishek Kumar, Elisabeth Werkmeister, Emmanuelle Leteurtre, Olivier Moralès, Nicolas Jonckheere, Isabelle Van Seuningen, Nadira Delhem
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Frontiers Media S.A. 2023-11-01
Sarja:	Frontiers in Immunology
Aiheet:	pancreatic adenocarcinoma galectin-9 regulatory T cells immunotherapy transgenic mouse model pancreatic intraepithelial neoplasm (PanIN)
Linkit:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1267279/full
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!